Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Precision Immunopsychiatric Pharmacological Probe of Adalimumab as an Anti-depressant

NCT07845604 is registered in ClinicalTrials.gov with Daniel Moriarity as lead sponsor.

NCT NCT07845604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07845604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Precision Immunopsychiatric Pharmacological Probe of Adalimumab as an Anti-depressant
Lead sponsor
Daniel Moriarity
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
September 30, 2031
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)